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andida spp. have become leading causes of lethal
bloodstream infections in countries with advanced
medical technology [1]. It is generally and correctly
understood that disseminated candidiasis is ‘‘an
opportunistic infection’’ that does not occur in healthy
people outside of hospitals. It is also incorrectly often said
that most patients who develop disseminated candidiasis are
‘‘immunocompromised’’. While neutropenia (but not
lymphocyte dysfunction, including that associated with HIV
infection) is indeed a well known risk factor for disseminated
candidiasis, patients with neutropenia actually comprise a
minority (,20%) of the population that develops
disseminated candidiasis [1]. The majority (.80%) of patients
who develop disseminated candidiasis are not neutropenic or
immunocompromised, and instead have alterations in
anatomical barrier function or commensal organism burden
due to central venous catheterization, parenteral nutrition,
surgical manipulation of the intestines, receipt of broad
spectrum antibacterial agents, and/or overgrowth of
commensal Candida [1]. Furthermore, even when neutropenia
is present as a predisposing risk factor, it is typically present
because of cancer chemotherapy, which typically also causes
disruption of the gastrointestinal mucosal barrier. Hence, the
precise role of speciﬁc immune dysfunction in predisposing
to disseminated candidiasis has been poorly understood to
date.
Enter Koh et al. [2]. These investigators have developed a
novel murine model of disseminated candidiasis in which
gastrointestinal colonization with C. albicans was induced. In
contrast, in the standard murine model of disseminated
candidiasis, mice are infected via tail vein injection directly
into the bloodstream. The standard tail vein model is
extremely useful because it accurately recapitulates infection
introduced into patients directly through catheters, its
clinical course is similar to untreated clinical disseminated
candidiasis, and it has been predictive of efﬁcacy of
antifungal agents against systemic infection [3–7]. However,
an advantage of the novel murine model presented by Koh et
al. is that it recapitulates the most common route of
infection, translocation of commensal Candida across
gastrointestinal mucosal surfaces into the bloodstream.
There have been previously established murine models of
candidal enteral colonization [8], including a facile model
recently published by Clemons at al. [9]. In some of these
models immunosuppression of the colonized animals led to
dissemination, but the immunosuppression was generally
with agents that simultaneously disrupted granulocyte and/or
enteric mucosa integrity [8]. Thus, by far the most signiﬁcant
aspect of the current publication is the clever way in which
the investigators sequentially disrupted speciﬁc host defense
elements to determine which protected against disseminated
candidiasis from a gastrointestinal source. Consistent with
clinical experience and prior murine studies [10,11], the
investigators found that depletion of lymphocytes did not
predispose to candidal dissemination. Furthermore, even
profound depletion of granulocytes (primarily neutrophils)
or tissue macrophages was insufﬁcient to enable trans-
mucosal dissemination to occur in most animals. These
depletion experiments were performed by administering
RB6-8C5 antibody (for granulocytes) or liposomal cladronate
(for macrophages), and hence spared the enteric mucosa
from the damage that normally occurs during myeloablation
by chemotherapy. Disruption of enteric mucosal integrity
with dextran sulfate was also, by itself, not sufﬁcient to induce
disseminated candidiasis. However, when an actual
chemotherapy agent (cyclophosphamide) that both ablated
neutrophils and also caused gut barrier disruption was
administered, lethal disseminated candidiasis developed.
Combinations of agents (methotrexate or dextran sulfate þ
RB6-8C5) that both caused enteric mucosal disruption and
depleted granulocytes also led to lethal disseminated
candidiasis.
It is surprising that the liver was the primary target organ
of infection in the new model because clinical hepatic
candidiasis is rare and is typically seen only in the most
profoundly immunocompromised patients. Furthermore, in
the tail vein model of murine disseminated candidiaisis, the
primary target organ of infection is the kidney, hepatic
infection occurs at markedly lower levels, and the liver clears
infection over time, even at rapidly lethal inocula [4,12]. In
another gastrointestinal colonization model in which
candidal dissemination was induced by administration of the
chemotherapy agent 5-ﬂuorouracil, livers were also more
frequently infected than kidneys from days 5 to 15, but by day
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burdens [9]. Whether or not other target organs would
become infected at later time points, whether the liver would
eventually clear the infection over time, and infection of
which organ best correlates with host outcome are questions
that merit additional study in this novel model.
Hence, important aspects of clinical disseminated
candidiasis have been recapitulated in the novel murine
model presented by Koh et al. Furthermore, the model builds
upon prior pathogenesis studies [8] and demonstrates that
the primary host defense mechanism by which mammals
defend ourselves against disseminated candidiasis is intact
anatomical surfaces (i.e., gut mucosal barrier and skin).
Phagocytes serve as a critical second line of defense against
disseminated candidiasis, coming in to play when organisms
are able to translocate across damaged anatomical barriers.
So, when we say that Candida is an opportunistic pathogen, we
can now state with conﬁdence that the ‘‘opportunity’’ for the
fungus to infect is primarily created by disruption of
anatomical barriers and secondarily by abrogation of
phagocytic numbers or function. “
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